Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study.
Sonia ZaibetVincent HautefeuilleEdouard AuclinAstrid LièvreDavid TougeronMathieu SarabiMarine GilabertJulie WasselinJulien EdelinePascal ArtruDominique BechadeClémence MorinAgnes DucoulombierGilles ManceauSimon PernotPublished in: British journal of cancer (2022)
In this study, Gem-Nab was associated with better DCR, PFS and OS compared with Gem alone in patients with mPA after FFX failure, at the cost of higher toxicity.